Biodesix strengthens financial position with equity issuance and amendment to term loan

Boulder, colo.--(business wire)---- $bdsx #patientsfirst--biodesix, inc. (nasdaq: bdsx), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the sale of 3,756,994 common shares on december 30, 2021 in an at-the-market offering that raised approximately $16.3 million in gross proceeds to fund repayment of its existing term loan. in addition, the company entered into a second amendment to its $30 million 2021 term loan (“second amendment”) on december 31, 2021, which includes modifi
BDSX Ratings Summary
BDSX Quant Ranking